Related Experiment Video
Updated: Jun 12, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Apixaban in acute coronary syndromes
Ganesan Karthikeyan1, John W Eikelboom
1Department of Cardiology, Cardiothoracic Sciences Center, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. karthik2010@gmail.com
Cardiovascular Therapeutics
|June 18, 2010
Summary
Apixaban, a direct factor Xa inhibitor, shows promise for managing acute coronary syndromes (ACS). Early data suggests its potential role in long-term anticoagulation therapy for ACS patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Anticoagulants are crucial in managing acute coronary syndromes (ACS).
- Long-term anticoagulation strategies for ACS require ongoing evaluation.
- Factor Xa inhibitors represent a novel therapeutic class.
Purpose of the Study:
- To review the evidence for anticoagulants in long-term ACS management.
- To present preliminary data on apixaban from the APPRAISE trial.
- To discuss the future potential of apixaban in ACS.
Main Methods:
- Review of existing literature on anticoagulants for ACS.
- Analysis of Phase 2 APPRAISE trial data for apixaban.
- Evaluation of safety and efficacy endpoints.
Main Results:
- Apixaban is an orally active, selective, direct factor Xa inhibitor.
- Preliminary data from the APPRAISE trial provides insights into apixaban's use.
- Evidence for long-term anticoagulation in ACS is critically reviewed.
Conclusions:
- Apixaban is under evaluation for ACS management.
- Further research is needed to establish apixaban's role in long-term ACS therapy.
- Apixaban may offer a future therapeutic option for ACS patients.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...